Immunocore’s Phase III IMCgp100-202 trial of tebentafusp compared to investigator’s choice for metastatic uveal melanoma (mUM) met the pre-defined boundaries for statistical significance of the primary endpoint of overall survival in its first pre-planned interim analysis.
Five Prime Therapeutics Inc., in collaboration Zai Lab Limited on the development of bemarituzumab – a novel therapy for front-line advanced non HER2+ gastric or gastroesophageal junction (GEJ) cancer – announced groundbreaking positive topline Phase II results.
Merck and Eisai announced new investigational data demonstrating positive top-line results from the Phase III KEYNOTE-581/CLEAR trial (Study 307).
Langland announced the appointment of Angela Rochelle as Account Director, Head of Diversity Initiatives in Clinical Trials.
Denmark-based Genmab A/S announced positive topline data from the second part of the Phase III CASSIOPEIA trial evaluating daratumumab (marketed as Darzalex) monotherapy as maintenance treatment compared to observation for patients with newly diagnosed multiple myeloma that are eligible for autologous stem cell transplant.
Ed Hudson, managing director at Create Health, discusses the increasing importance of brand in pharma – especially in light of increased competition.
Andrea Bastek – Director of Innovation at Florence, the largest eISF + Remote Site Access platform in clinical research – discusses three ways in which sponsors and CROs can increase compliance with a purpose-built, site-centric, remote access platform.
Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the U.S. Food and Drug Administration for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.
Junshi Biosciences, based in Shanghai, China, announced that an Independent Monitoring Committee (IDMC) decided the company’s Phase III JUPITER-02 trial had met the pre-specified primary endpoint at the interim analysis.
W2O announced the creation of Hū, the first-of-its kind Patient Activation Organization (PAO).